Phaseline

Targets › IL3RA

IL3RA (Interleukin-3 receptor subunit alpha): drug programs, companies and trials

8 programs from 8 companies in 22 trials: 17 Phase 1, 5 Phase 2; Oncology; next expected readout Dec 2026.

Cell surface receptor for IL3 expressed on hematopoietic progenitor cells, monocytes and B-lymphocytes that controls the production and differentiation of hematopoietic progenitor cells into lineage-restricted cells. Ligand stimulation rapidly induces hetrodimerization with IL3RB, phosphorylation and enzyme activity of effector proteins such as JAK2 and PI3K that play a role in signaling cell proliferation and…. (UniProt, P26951)

Open in Phaseline: the race on IL3RA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AbbViePivekimab Sunirine
Interleukin-3 receptor subunit alpha binding agent
IL3RAPhase 2Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell NeoplasmDec 2026
Stemline TherapeuticsTagraxofusp
Interleukin-3 receptor subunit alpha binding agent; Elongation factor 2 inhibitor
IL3RA, EEF2Phase 2Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Myelofibrosis …Feb 2028
Children's Oncology GroupFlotetuzumab
Interleukin-3 receptor subunit alpha binding agent; T cell surface glycoprotein CD3 binding agent
IL3RA, CD3E, CD3G, CD3DPhase 1Recurrent Acute Myeloid LeukemiaMar 2027
Aptevo TherapeuticsAPVO436
CD123-targeting bispecific T-cell engager (BiTE)
IL3RAPhase 1Acute Myeloid Leukemia (AML)Oct 2027
Fondazione Matilde Tettamanti Menotti De Marchi OnlusCARCIK CD123/33
CAR-T cell therapy targeting CD123 and CD33
IL3RA, ITGAMPhase 1AML (Acute Myeloid Leukemia)Oct 2028
Orum Therapeutics USAORM-1153
anti-CD123 antibody-drug conjugate
IL3RAPhase 1CD123+ Acute Myeloid LeukemiaDec 2028
Stephan Grupp MD PhDCART123 cells
anti-CD123 chimeric antigen receptor T cells with TCRζ/4-1BB costimulatory domains
IL3RAPhase 1Acute Myeloid Leukemia (AML)May 2029
St. Jude Children's Research HospitalCD123-CAR T
CAR-T cell therapy targeting CD123 (IL3RA) antigen on leukemic and MDS cells
IL3RAPhase 1AML/MDSJul 2029

Conditions

Acute Myeloid Leukemia (8) Blastic Plasmacytoid Dendritic Cell Neoplasm (2) Acute Myeloid Leukemia (AML) (2) CD123+ Acute Myeloid Leukemia (1) AML/MDS (1) AML (Acute Myeloid Leukemia) (1) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (1) Myelofibrosis (1) Chronic Myelomonocytic Leukemia (1) Refractory Acute Myeloid Leukemia (1) Hematologic Malignancy (1) Acute Myeloid Leukaemia (AML) (1)

Modalities

mixed (4), small molecule (4)

Companies

AbbVie (1) Orum Therapeutics USA (1) St. Jude Children's Research Hospital (1) Fondazione Matilde Tettamanti Menotti De Marchi Onlus (1) Aptevo Therapeutics (1) Stemline Therapeutics (1) Stephan Grupp MD PhD (1) Children's Oncology Group (1)

Related targets

ITGAM (1) EEF2 (1) CD3E (1) CD3G (1) CD3D (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.